GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial for Gepotidacin in Uncomplicated Urogenital Gonorrhoea (GC)

London, UK 26 February 2024 GSK plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials